Navigation Links
Significant Generic Erosion Will Cause Sales of Dyslipidemia Drugs to Decline by $3.6 Billion by 2016
Date:3/19/2008

Statins Will Continue to Dominate Market Despite Patent Expiries and Increased Use of Fixed-Dose Combinations, According to a New Report from

Decision Resources

WALTHAM, Mass., March 19 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that sales of dyslipidemia therapies will decline from $28 billion in 2006 to $24.4 billion in 2016 owing to significant generic erosion, triggered particularly by the 2006 U.S. patent expiry of Merck's Zocor and the U.S. and European patent expiries of Pfizer's Lipitor beginning in 2010.

The new Pharmacor report entitled Dyslipidemia finds that statins will continue to dominate the dyslipidemia drug market by claiming more than 70 percent patient share in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. However, the sales share of statins will decline from $21 billion in 2006 to $7.8 billion in 2016 owing to generic erosion and greater use of fixed-dose combination therapies that offer dual modes of action and/or modulate high-density lipoprotein (HDL) in addition to low- density lipoprotein (LDL) cholesterol. The fixed-dose combinations class will capture 30 percent of the dyslipidemia market in 2016.

The report also finds that physicians will increasingly prescribe treatment aimed at aggressive LDL targets in high-risk patients, which will benefit more potent agents such as AstraZeneca's Crestor and add-on therapies such as Merck/Schering-Plough's Zetia/Ezetrol. Aggressive treatment will also boost uptake of novel LDL-lowering therapies such as lapaquistat, Takeda's novel squalene synthase inhibitor, which will be used in polypharmacy regimens.

"Although statins are entrenched as the first-line therapy of choice for the vast majority of dyslipidemia patients and have achieved success in lowering both LDL and the risk of heart attacks, the prevalence of both coronary heart disease and mortality remain unacceptably high," said Donny Wong, Ph.D., principal analyst at Decision Resources. "As a result, the medical community is increasingly targeting non-LDL lipid abnormalities, and despite the recent discontinuation of Pfizer's torcetrapib in Phase III development, physicians believe that well-tolerated therapies that target low or dysfunctional HDL can still play a vital role in primary and secondary prevention."

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be

trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Carnegie Mellon study shows just listening to cell phones significantly impairs drivers
2. NeurogesX to Present at Susquehanna Financial Groups 2nd Annual SIGnificant Options in Healthcare Conference
3. Novavax CEO to Present at Susquehannas Second SIGnificant Options in Healthcare Conference
4. Abaxis, Inc. to Present at the Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
5. Idenix Pharmaceuticals to Present at the SIGnificant Investment Options in Healthcare Conference
6. Advanced Life Sciences to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference
7. Significant Growth for Pinstripe Leads to Need for Larger Facility
8. Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference
9. AAAS symposium to address significant effects of the male parent in reproductive success
10. Peter G. Peterson Commits $1 Billion Toward Solving Americas Most Significant Economic Challenges
11. Surprising New Research Indicates that Significant Numbers of Children as Young as 11 are Engaging in Sexual Activity and that Dating Violence and Abuse are Part of Their Relationships
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Regular gym ... find themselves having to wait longer to access the treadmills. It’s a predictable trend. ... resolutions to lose weight and get in shape by joining gyms, starting new walking ...
(Date:2/5/2016)... ... ... Dr. Justin Scott and Dr. Lydia Muccioli of Pure Dental Health ... in need. The event is scheduled to take place on February 27, 2016 from ... dental care to community members in need. Each patient will be given the opportunity ...
(Date:2/5/2016)... ... February 05, 2016 , ... Health and wellness is a ... individuals in the event they are experiencing an illness. Migraines are a severe form ... are afflicted with migraines would not wish the pain on their worst enemy, the ...
(Date:2/5/2016)... ... 2016 , ... –This week, Atascadero water heater company First Call Plumbing ... To view the report, click here or see below. , There ... pros and cons, the type chosen is almost entirely up to personal preference. However, ...
(Date:2/4/2016)... ... February 04, 2016 , ... American Addiction Centers ... the start of Project HoldSpace. Through the partnership, the two organizations seek to ... youth between the ages of 13 and 18. Currently focused on Ohio schools, ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... 2016  Patients in Alabama seeking ... therapy no longer have to travel out of state. ... Urology Centers of Alabama to provide a total ... qualifying patients. Alabama is ... of prostate cancer using many different modalities. They are the ...
(Date:2/5/2016)... 2016 --> ... that the global active pharmaceuticals ingredients (APIs) market stood ... reach US$185.9 bn by 2020. It is expected to ... 2020. The title of the report is "Active Pharmaceutical ... and by Therapeutic Area) - Global Industry Analysis, Size, ...
(Date:2/5/2016)... 2016 Site Profile: --> ... - The Speech Recognition People, announced their latest primary healthcare case ... care, reduce turnaround times and to save the practice money. ... since 2013 Challenge: --> ,- Wirral CCG ... - Six doctors ,- Wirral CCG ,- VoicePower client since 2013 ...
Breaking Medicine Technology: